42
Participants
Start Date
February 28, 2009
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Bosutinib
300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
exemestane
25 mg tablet once daily
Exemestane
25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
Pfizer Investigational Site, Brussels
Pfizer Investigational Site, Budapest
Pfizer Investigational Site, Wilrijk
Pfizer Investigational Site, Leuven
Pfizer Investigational Site, Liège
Pfizer Investigational Site, South Brisbane
Pfizer Investigational Site, New York
Pfizer Investigational Site, Bethlehem
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Madrid
Pfizer Investigational Site, Lake Worth
Pfizer Investigational Site, Valencia
Pfizer Investigational Site, Joliet
Pfizer Investigational Site, Detroit
Pfizer Investigational Site, Seattle
Pfizer Investigational Site, Beijing
Pfizer Investigational Site, Mumbai
Pfizer Investigational Site, Pune
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Boston
Pfizer Investigational Site, New Brunswick
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Kelowna
Pfizer Investigational Site, Hong Kong
Pfizer Investigational Site
Pfizer Investigational Site, Olsztyn
Pfizer Investigational Site, Lynnwood
Pfizer Investigational Site, Barcelona
Lead Sponsor
Pfizer
INDUSTRY